Antibody therapies constitute a vast global market: currently valued at over $250 billion, the market for antibodies is ...

A revolutionary new type of "Trojan horse" cancer therapy, now being deployed under the National Health Service in England, ...

A new feature added to the state’s All Payer Claims Database lets users compare average prescription costs, helping avoid ...

As startups navigate the growing biotech sector in Wales, here are five biotech companies that are making waves in 2025.

Will the U.S. government adopt price controls on prescription drugs? If so, what would they look like? Seeking Alpha analysts ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Donanemab and lecanemab are targeted antibody drugs that slow down the early stages of Alzheimer’s. They represent a huge step forward in research because they target a known cause of the disease, ...

Two drugs to treat Alzheimer’s disease have been rejected for use on the NHS because their benefits are “too small” to justify their cost, the health spending watchdog has said. The National Institute ...

AstraZeneca, Pfizer and more are leveraging the computational power of AI to better design trials, predict the potential efficacy and safety profiles of their molecules and synthesize massive ...

Beyond belrestotug, iTeos is developing an ENT1 inhibitor and an anti-TREM2 antibody, both of which are in phase 1 cancer studies. GSK’s exit from the TIGIT race extends a string of dropouts in ...

On the heels of President Trump’s Monday announcement of an executive order to slash prescription drug prices in the U.S., the spotlight is on current costs and how much Americans could save.